Ventria Bioscience的分公司InVitria 成立的目標是為生物技術行業提供**產品，以改善細胞培養和生物制造。InVitria通過允許客戶從其基于細胞的過程中消除動物成分來實現這一點。拆除這些組件有助于提高一致性，**性和效率。InVitria的產品是在我們位于堪薩斯州Junction City的生產設施中生產的重組蛋白。這些產品在生命科學行業有很多用途，包括再生醫學，細胞治療，生物制造，疫苗，診斷和醫療設備。
諸如胎牛血清（FBS），牛和人血清白蛋白以及牛和人轉鐵蛋白的動物組分已經在許多生物過程中成為流行的成分，但是在二十世紀九十年代，科學家開始尋找清除血清和其它動物產品的方法關注產品質量，**和動物管理。動物產品是不受歡迎的，因為它們具有傳播感染性物質如朊病毒（瘋牛病）和病毒（HIV）的風險。另外，動物組分和血液衍生產品是不確定的，導致批次間的高度差異。由于這些原因，美國食品和藥物管理局（FDA），歐洲藥品管理局（EMA）和其他監管機構不鼓勵使用這些動物成分。
“我喜歡與負責批準InVitria作為供應商的客戶審計師合作。他們來自世界上一些*成功的生物制藥和生命科學公司，所以他們的期望很高。我們的期望也很高，并導致成功的結果。“
InVitria與生物制藥公司，**大學，國家衛生研究院和疾病控制中心進行了多項研究合作，以加強我們的產品開發和發現新的產品機會。對于學術研究人員，InVitria通過BioShare計劃提供支持。
InVitria –Performance. Defined.
InVitria, a division of Ventria Bioscience, was founded with the goal of providing the biotechnology industry with innovative products to improve cell culture and biomanufacturing. InVitria does this by allowing customers to eliminate animal components from their cell-based processes. Removing these components helps improve consistency, safety and efficiency. InVitria’s products are recombinant proteins that are manufactured in our manufacturing facility in Junction City, Kansas. These products have many uses across the life science industry including in regenerative medicine, cellular therapy, biomanufacturing, vaccines, diagnostics and medical devices.
Animal-components such as fetal bovine serum (FBS), bovine and human serum albumin, and bovine and human transferrin have been popular ingredients in many biological processes, but in the 1990’s scientists began searching for ways to remove serum and other animal products due to concerns about product quality, safety and animal stewardship. Animal products are undesirable because they pose a risk of transmitting infectious agents such as prions (Mad Cow Disease) and virus (HIV). In addition, animal components and blood derived products are undefined leading to high batch-to-batch variation. For these reasons, the Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory bodies discourage use of these animal components.
To date, InVitria has developed and commercialized eight recombinant proteins and cell culture media supplements. InVitria’s product development team has an active program to expand this product line based on customer needs.
At InVitria, we are proud of our team and our partnerships.
InVitria’s team is committed to providing innovative solutions to the most pressing cell culture challenges today.
“Helping customers integrate these animal component free products to improve their processes and reach their commercial objectives is what excites me about InVitria”
– Steve Pettit, Ph.D. Director, Cell Culture
“I like working with our customer auditors who are responsible for approving InVitria as a vendor. They come from some of the most successful biopharmaceutical and life science companies in the world, so their expectations are high. Our expectations are also high and that leads to a successful outcome.”
– Pat Smith, Director, Quality
As a Division of Ventria Bioscience, InVitria has access to Ventria’s Board of Directors and their expertise and successful history. These leaders include:
-
a member of the National Academies of Science and 2003 Biotechnology Heritage Award Winner,
-
former Chairman and CEO of the largest plant biotechnology company in the world,
-
two founders of Chiron Corporation (now Novartis),
-
former President of Johnson & Johnson’s diagnostics business,
-
Chairman of PRA International, a leading clinical trial CRO,
-
the former President of Millipore’s Bioscience Division, and
-
two General Partners of leading healthcare venture capital firms.
Together, the Ventria Board of Directors have amassed over 120 years of biotechnology experience, registered over 145 patents, and published over 600 scientific papers. Click to read more about the Board of Directors
InVitria has partnered with two worldwide distributors, Sigma-Aldrich and Fisher Scientific . Our distribution network also includes several regional distributors for customers in North America, Europe, Asia and Australia. This extensive distribution network provides our customers with a full compliment of purchasing, logistics and product support options to best fit their needs. Click to read more about our Distributors (Link to new distributors page)
At InVitria, we are passionate about our products and our customers.
”We are committed to provide safe, cost-effective solutions to the industry’s biggest challenges: improving productivity and enhancing consistency by removing animal derived components”
Scott Deeter, President
InVitria has several research collaborations with biopharmaceutical companies, leading Universities, the National Institutes of Health and the Centers for Disease Control to further our product development and identify new product opportunities. For academic researchers, InVitria offers support through its BioShare program.
At InVitria, we are dedicated to quality and safety.
As part of Ventria Bioscience, InVitria utilizes Ventria’s patented recombinant protein manufacturing technology called ExpressTec.
“ExpressTec provides a safe, affordable and sustainable manufacturing platform for InVitria to manufacture its recombinant proteins in a completely animal-free system”
Ning Huang, Ph.D., Vice President Research and Development.
InVitria,的一個部門Ventria Bioscience,成立的目的,為生物技術產業提供**產品,提高細胞培養和生物制造。InVitria通過允許顧客消除動物組件從他們的細胞過程。刪除這些組件有助于提高一致性、**性和效率。InVitria的產品是在我們的工廠生產重組蛋白在結城,堪薩斯州。這些產品有許多使用整個生命科學行業包括再生醫學、細胞療法,為生物疫苗、診斷和醫療設備。
Animal-components如胎牛血清的邊后衛,牛和人血清白蛋白和牛和人類轉鐵蛋白一直流行的成分在許多生物過程,但在1990年代,科學家們開始尋找方法去除血清和其他動物產品因擔心產品質量,**和動物管理。動物產品是不可取的因為它們構成傳播傳染性病原體的風險如朊病毒(瘋牛病)和病毒(HIV)。此外,動物成分和血液衍生產品定義導致高批次變化。由于這些原因,美國食品和藥物管理局(FDA),歐洲藥品局(EMA)和其他監管機構阻止這些動物組件的使用。
